Examiner: TAO, BIN

Tech Center 1600 • Art Units: 1625

This examiner grants 0% of resolved cases

Performance Statistics

Allow Rate

-60.0% vs TC avg

Total Applications

Interview Lift

1175

Avg Prosecution Days

Based on 0 resolved cases, 2023–2026

§101 Eligibility

31.7%

§102 Novelty

34.2%

§103 Obviousness

17.1%

§112 Clarity

App #	Title	Status	Assignee
18577071	Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis	Non-Final OA	Daewoong Pharmaceutical Co., Ltd.
18481723	CRYSTALLINE FORMS OF A PARP1 INHIBITOR	Non-Final OA	XinThera, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.